On a smooth protein surface that has eluded cancer researchers for forty years, a new drug called daraxonrasib has finally found purchase—and the results are reshaping what scientists thought possible. Developed by Revolution Medicines in Redwood City, California, this daily pill represents a breakthrough against the RAS family of proteins, molecular switches that oncologists have long called "undruggable" because their slippery surfaces offer few handholds for conventional medications.
The discovery matters because RAS mutations are foundational to cancer. When a single DNA letter mutates in a RAS gene, it locks these molecular switches permanently in the "on" position, commanding cells to grow and divide without end. This mechanism was first identified in 1982, sparking nearly four decades of frustration as drug developers struggled to target proteins that looked, to molecules, like blank rock faces. The first approved RAS inhibitor didn't reach patients until 2021—nearly 40 years later—and it could only target one of the three RAS family members, limiting its use to a small fraction of patients.
Daraxonrasib takes a different approach. Rather than trying to grip the slippery protein directly, it binds to a partner molecule that helps RAS proteins fold into their final shape, essentially hitching a ride on the active protein to shut it down. More importantly, it works against all three RAS family members, vastly expanding its potential reach. In a trial of 500 patients worldwide with advanced pancreatic cancer, those taking daraxonrasib lived an average of 13.2 months with minimal pain and side effects, primarily a rash. Patients on chemotherapy survived roughly 6.6 months and endured more severe toxicity. That's nearly double the survival time with substantially better quality of life.
The drug doesn't work miracles. It's not a cure. But in pancreatic cancer—one of the deadliest malignancies—those extra 13 months matter enormously to patients and families. The results have electrified the cancer research community because they represent proof that the "undruggable" proteins can actually be tackled, just not through the strategies researchers tried for decades. If approved, a daily pill would also be far more accessible and affordable than personalized cell therapies like CAR-T, which remain out of reach for most patients globally.
What makes this moment even more significant is what comes next. Scientists are now using AI-based tools to accelerate the hunt for drugs targeting other undruggable proteins, particularly p53, known as the "guardian of the genome" for orchestrating over 300 genes involved in DNA repair and cell death. Since its discovery in 1979, p53 mutations have haunted researchers across multiple cancer types, but the protein presents the same smooth-surfaced challenge as RAS. With AI compressing years of molecular chemistry into months or weeks, researchers believe a new generation of undruggable-protein inhibitors could soon follow daraxonrasib into the clinic.
For cancer patients, the message is clear: what seemed impossible forty years ago, and unlikely just two years ago, is now real. The molecular switches that fuel some of humanity's most lethal cancers are finally losing their grip.